Skip to content


Volume 9 Supplement 2

AIDS Vaccine 2012

  • Oral presentation
  • Open Access

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

  • WB Williams1,
  • K Jones1,
  • A Krambrink2,
  • D Grove2,
  • P Liu1,
  • NL Yates1,
  • MA Moody1,
  • G Ferrari1,
  • J Pollara1,
  • Z Moodie2,
  • CA Morgan2,
  • H Liao1,
  • DC Montefiori1,
  • C Ochsenbauer3,
  • J Kappes3,
  • S Hammer4,
  • J Mascola5,
  • R Koup5,
  • L Corey6,
  • G Nabel5,
  • P Gilbert2,
  • G Churchyard7,
  • M Keefer8,
  • BS Graham5,
  • BF Haynes1 and
  • GD Tomaras1
Retrovirology20129(Suppl 2):O55

Published: 13 September 2012


ADCC ActivityVaccine RegimenBinding Gp140Antigen Specific MemoryProtein Boost


The phase II DNA prime, rAd5 boost vaccine (HVTN 204) exhibited sufficient safety and immunogenicity to advance into a phase IIb efficacy trial (HVTN 505) in Ad5 seronegative volunteers in the US. In the RV144 ALVAC prime, A/E gp120 protein boost trial, levels of V1V2 IgG antibodies significantly correlated with decreased risk of infection.


Sera from 203 vaccinees receiving VRC-HIVDNA016-00-VP DNA (m 0,1,2), and VRC-HIVADV014-00-VP rAd5 (m 6), at two weeks post rAd5 boost, and 208 placebos were examined for binding gp140 and gp120 recombinant proteins, gp41, and an antigen panel of 16 V1V2 IgG scaffolds representing clades A, B and C V1V2 sequences. A subset of vaccinees and placebo was screened for binding CD4BS antigens. Monoclonal antibodies were generated from antigen specific memory B cell sorts and tested for binding, neutralization, ADCC and virion capture.


Clade A and B V1V2 IgG antibodies were elicited in 38.4% and 19.2% of vaccinees, respectively. A clonal lineage of 3 gp41 mAbs (CH69, CH70, CH71), and a V3-specific gp120 mAb (CH73) were generated from vaccinees. The gp41 mAbs captured infectious HIV-1 transmitted/founder viruses, while CH73 mediated ADCC activity against subtypes B and C infected cells, neutralized subtypes B and C tier 1A viruses, and bound multiple Envs of subtypes A, B and C.


The phase II multi-clade DNA prime, rAd5 boost vaccine regimen elicited antibody responses to multiple epitope specificities, including V1V2, V3, and gp41. CH69-CH71 and CH73 mAbs represent the initial human mAbs from HVTN 204 vaccine recipients, and reflect the functional profile of vaccine-elicited antibodies. These data suggest that the HVTN 505 Phase IIb efficacy study using this same vaccine regimen may provide an opportunity to examine a diversity of antibody specificities that have been hypothesized as a correlate of HIV-1 infection risk.

Authors’ Affiliations

Duke Human Vaccine Institute, Duke University Medical Center, Durham, USA
SCHARP, Fred Hutchinson Cancer Research Center, Seattle, USA
Department of Medicine, University of Alabama at Birmingham, Birmingham, USA
Columbia University Medical Center, New York, USA
Vaccine Research Center, National Institute of Allergy and Infectious, Bethesda, USA
University of Washington, Seattle, USA
The Aurum Institute, Johannesburg, South Africa
Division of Infectious Disease, University of Rochester Medical Center, Rochester, USA


© Williams et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.